MED

What Should Investors Know About MEDIFAST INC (MED) Stock?

MEDIFAST INC logged a -0.4% change during today's afternoon session, and is now trading at a price of $74.64 per share. On average, analysts give it a target price of $73.0.

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The small-cap company is based in the United States. MEDIFAST INC currently returns an annual dividend yield of 8.8%.

Make Sure to Consider the Following Before Buying MEDIFAST INC:

  • MEDIFAST INC has moved -38.6% over the last year.

  • MED has a forward P/E ratio of 9.7 based on its EPS guidance of 7.67.

  • Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 15.6%.

  • The company has a price to earnings growth (PEG) ratio of 0.4.

  • Its Price to Book (P/B) ratio is 4.17

MEDIFAST INC Has Irregular Cash Flows

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 188,874 14,601 174,273 -2.03
2022 194,570 16,681 177,889 194.83
2021 94,545 34,209 60,336 -56.69
2020 145,196 5,887 139,309 87.74
2019 84,261 10,058 74,203 32.8
2018 60,816 4,940 55,876

MEDIFAST INC's free cash flows have a decent average of $113.65 Million over the last 6 years, but they are highly variable since their coefficient of variability is 224.16%. The compounded average growth rate over this period is 22.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS